Pharma Deko Plc (NGX: PHARMDEKO)
Nigeria
· Delayed Price · Currency is NGN 1.830
0.00 (0.00%)
At close: Oct 14, 2024
Pharma Deko Income Statement
Financials in millions NGN. Fiscal year is January - December.
Millions NGN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '22 Dec 31, 2022 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 469.58 | 469.58 | 503.55 | 460.84 | 484.57 | 1,024 | Upgrade
|
| Revenue Growth (YoY) | -6.75% | -6.75% | 9.27% | -4.90% | -52.67% | -35.75% | Upgrade
|
| Cost of Revenue | 435.21 | 435.21 | 413.08 | 405.33 | 314.22 | 632.74 | Upgrade
|
| Gross Profit | 34.37 | 34.37 | 90.47 | 55.51 | 170.35 | 391.06 | Upgrade
|
| Selling, General & Admin | 194.72 | 194.72 | 217.56 | 381.94 | 530.8 | 657.34 | Upgrade
|
| Other Operating Expenses | -28.03 | -28.03 | -15.46 | -1.39 | -0.07 | -11.12 | Upgrade
|
| Operating Expenses | 166.69 | 166.69 | 202.11 | 380.54 | 530.72 | 646.22 | Upgrade
|
| Operating Income | -132.32 | -132.32 | -111.64 | -325.04 | -360.37 | -255.15 | Upgrade
|
| Interest Expense | -9.9 | -9.9 | -2.83 | -2.21 | -7.45 | -0.94 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.6 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.61 | 0.61 | - | 0.03 | 0.76 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -141.61 | -141.61 | -114.47 | -327.22 | -366.46 | -255.98 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.02 | 3.16 | - | - | Upgrade
|
| Other Unusual Items | - | - | 45.96 | - | 90 | - | Upgrade
|
| Pretax Income | -141.61 | -141.61 | -68.49 | -324.05 | -276.46 | -255.98 | Upgrade
|
| Income Tax Expense | - | - | 1.3 | 1.15 | 2.42 | 9.28 | Upgrade
|
| Net Income | -141.61 | -141.61 | -69.79 | -325.21 | -278.88 | -265.26 | Upgrade
|
| Net Income to Common | -141.61 | -141.61 | -69.79 | -325.21 | -278.88 | -265.26 | Upgrade
|
| Shares Outstanding (Basic) | 217 | 217 | 217 | 218 | 216 | 217 | Upgrade
|
| Shares Outstanding (Diluted) | 217 | 217 | 217 | 218 | 216 | 217 | Upgrade
|
| Shares Change (YoY) | - | - | -0.61% | 0.96% | -0.57% | 3.50% | Upgrade
|
| EPS (Basic) | -0.65 | -0.65 | -0.32 | -1.49 | -1.29 | -1.22 | Upgrade
|
| EPS (Diluted) | -0.65 | -0.65 | -0.32 | -1.49 | -1.29 | -1.22 | Upgrade
|
| Free Cash Flow | -48.32 | -48.32 | -69.54 | 103.88 | 2.71 | -64.44 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.22 | -0.32 | 0.48 | 0.01 | -0.30 | Upgrade
|
| Gross Margin | 7.32% | 7.32% | 17.97% | 12.04% | 35.16% | 38.20% | Upgrade
|
| Operating Margin | -28.18% | -28.18% | -22.17% | -70.53% | -74.37% | -24.92% | Upgrade
|
| Profit Margin | -30.16% | -30.16% | -13.86% | -70.57% | -57.55% | -25.91% | Upgrade
|
| Free Cash Flow Margin | -10.29% | -10.29% | -13.81% | 22.54% | 0.56% | -6.29% | Upgrade
|
| EBITDA | -63.29 | -63.29 | -43.76 | -254.1 | -281.11 | -179.32 | Upgrade
|
| EBITDA Margin | -13.48% | -13.48% | -8.69% | -55.14% | -58.01% | -17.52% | Upgrade
|
| D&A For EBITDA | 69.03 | 69.03 | 67.88 | 70.93 | 79.26 | 75.83 | Upgrade
|
| EBIT | -132.32 | -132.32 | -111.64 | -325.04 | -360.37 | -255.15 | Upgrade
|
| EBIT Margin | -28.18% | -28.18% | -22.17% | -70.53% | -74.37% | -24.92% | Upgrade
|
| Advertising Expenses | - | - | 7.64 | 7.31 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.